Private Asset Management Inc. Purchases 44 Shares of Becton, Dickinson and Company (NYSE:BDX)

Private Asset Management Inc. grew its position in Becton, Dickinson and Company (NYSE:BDX) by 3.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,368 shares of the medical instruments supplier’s stock after purchasing an additional 44 shares during the quarter. Private Asset Management Inc.’s holdings in Becton, Dickinson and were worth $333,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. BlackRock Inc. raised its position in shares of Becton, Dickinson and by 4.0% in the fourth quarter. BlackRock Inc. now owns 22,231,734 shares of the medical instruments supplier’s stock valued at $5,562,827,000 after purchasing an additional 852,823 shares during the period. Morgan Stanley raised its position in shares of Becton, Dickinson and by 3.4% in the fourth quarter. Morgan Stanley now owns 7,844,715 shares of the medical instruments supplier’s stock valued at $1,962,905,000 after purchasing an additional 259,989 shares during the period. Fiera Capital Corp raised its position in shares of Becton, Dickinson and by 3.5% in the fourth quarter. Fiera Capital Corp now owns 3,946,962 shares of the medical instruments supplier’s stock valued at $987,609,000 after purchasing an additional 132,100 shares during the period. Wells Fargo & Company MN raised its position in shares of Becton, Dickinson and by 4.3% in the fourth quarter. Wells Fargo & Company MN now owns 3,803,032 shares of the medical instruments supplier’s stock valued at $951,595,000 after purchasing an additional 157,793 shares during the period. Finally, Flossbach Von Storch AG raised its position in shares of Becton, Dickinson and by 21.9% in the fourth quarter. Flossbach Von Storch AG now owns 3,181,619 shares of the medical instruments supplier’s stock valued at $796,105,000 after purchasing an additional 572,178 shares during the period. 83.22% of the stock is currently owned by institutional investors.

Several brokerages have recently issued reports on BDX. Morgan Stanley upgraded shares of Becton, Dickinson and from an “equal weight” rating to an “overweight” rating and raised their price objective for the stock from $262.00 to $297.00 in a research note on Tuesday, December 15th. Piper Sandler raised their price objective on shares of Becton, Dickinson and from $275.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 4th. Citigroup raised their price objective on shares of Becton, Dickinson and from $273.00 to $280.00 and gave the stock a “neutral” rating in a research note on Friday, February 5th. The Goldman Sachs Group downgraded shares of Becton, Dickinson and from a “conviction-buy” rating to a “buy” rating in a research note on Tuesday, December 15th. Finally, Zacks Investment Research downgraded shares of Becton, Dickinson and from a “buy” rating to a “hold” rating and set a $276.00 price objective on the stock. in a research note on Wednesday, January 13th. Seven research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $281.08.

BDX opened at $244.02 on Thursday. Becton, Dickinson and Company has a fifty-two week low of $219.50 and a fifty-two week high of $284.97. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.54 and a quick ratio of 1.07. The firm’s fifty day moving average price is $243.71 and its two-hundred day moving average price is $243.60. The company has a market capitalization of $70.90 billion, a P/E ratio of 89.38, a P/E/G ratio of 2.34 and a beta of 0.79.

Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings results on Wednesday, February 3rd. The medical instruments supplier reported $4.55 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.14 by $1.41. The firm had revenue of $5.32 billion for the quarter, compared to the consensus estimate of $4.87 billion. Becton, Dickinson and had a net margin of 5.11% and a return on equity of 13.30%. The business’s revenue was up 25.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.65 earnings per share. On average, equities research analysts expect that Becton, Dickinson and Company will post 12.5 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, March 31st. Shareholders of record on Wednesday, March 10th were issued a dividend of $0.83 per share. The ex-dividend date of this dividend was Tuesday, March 9th. This represents a $3.32 dividend on an annualized basis and a dividend yield of 1.36%. Becton, Dickinson and’s payout ratio is presently 32.55%.

Becton, Dickinson and Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps, dedicated disposables, IV fluids, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Further Reading: How to Profit and Limit Losses With Stop Orders

Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.